Education
About Us
Working with TipRanks
Follow Us
UCB SA (UCBJY)
OTHER OTC:UCBJY
Earnings Data
Report Date
Feb 26, 2026Before Open (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
2.22Last Year’s EPS
1.55Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call presents a largely positive outlook with UCB showcasing strong revenue growth, successful product launches, and a robust pipeline. However, challenges such as pricing pressures, currency headwinds, and potential tariffs introduce some uncertainties.Company Guidance
Record Growth in Revenue
UCB reported a 26% growth in net sales, reaching EUR 3.32 billion in the first half of 2025, significantly boosted by BIMZELX performance and other recently launched assets.
Successful Product Launches
BIMZELX sales quadrupled to close to EUR 800 million, with strong growth in all regions and indications. The company also saw significant growth in FINTEPLA, RYSTIGGO, and ZILBRYSQ.
Pipeline Development
UCB is advancing its pipeline with multiple new indications and promising clinical results, including a 90% survival rate in TK2 deficiency disorder and positive Phase III results for FINTEPLA in CDKL5 deficiency disorder.
Upgraded Financial Guidance
UCB increased its revenue guidance to at least EUR 7 billion for the full year 2025 and an EBITDA margin to at least 30%, reflecting confidence in continued strong performance.
Strong Market Position
BIMZELX achieved significant market penetration, reaching 82,000 patients across 50 countries, and capturing dynamic market share in psoriasis and rheumatology.
UCBJY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
UCBJY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Jul 31, 2025 | $106.42 | $108.99 | +2.41% |
Feb 27, 2025 | $95.14 | $93.31 | -1.92% |
Jul 25, 2024 | $79.08 | $81.17 | +2.64% |
Feb 28, 2024 | $52.03 | $56.17 | +7.96% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does UCB SA (UCBJY) report earnings?
UCB SA (UCBJY) is schdueled to report earning on Feb 26, 2026, Before Open (Confirmed).
What is UCB SA (UCBJY) earnings time?
UCB SA (UCBJY) earnings time is at Feb 26, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is UCBJY EPS forecast?
UCBJY EPS forecast for the fiscal quarter 2025 (Q4) is 2.22.